About company
They are a newly incorporated blank check company. While they may pursue an acquisition opportunity in any business, industry, sector, or geographical location, they intend to focus on targets in industries where they believe their management team and their founder’s expertise will provide them with a competitive advantage, including biopharma or technology enabled business-to-consumer (“B2C”) industries globally. They believe the innovations in these sectors that have emerged in recent years, partly as a response to the broad social, economic, and behavioral changes arising from the COVID-19 global pandemic, provide attractive opportunities to target high growth companies with technology and business model innovation. For example, by virtue of their team’s industry network and their founder’s recent investments, they have turned their attention towards certain sub-segments in healthcare, including neurology and rare diseases, where they believe they can find attractive targets for their business combination. While they will target companies globally, they believe that their team’s strong ties to Asia gives them an advantage in sourcing Asia-originated biopharma companies with global aspirations for the purposes of a business combination in the U.S. market. They believe favorable innovation and regulatory trends in Asia should position them well for such opportunities.